4CPS-299 Patients’ misconceptions following initiation of antineoplastic treatment for colorectal cancer (original) (raw)
Efficacy of erlotinib in patients with advanced non-small cell lung cancer
Nick Pavlakis
Anti-Cancer Drugs, 2011
View PDFchevron_right
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials
Alberto Zaniboni
View PDFchevron_right
Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer
Christine B Boers-Doets
European Journal of Oncology Nursing, 2010
View PDFchevron_right
Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study
Dimitrios Trafalis
Oncology Letters, 2010
View PDFchevron_right
Efficacy and safety of erlotinib in previously treated advanced non-small cell lung cancer | Daha önce tedavi edilmiflşleri evre küçük hücreli di{dotless}şi{dotless} akciǧer kanserli hastalarda erlotinibin güvenlik ve etkinliǧi
Erkan Arpaci
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2013
View PDFchevron_right
Gefitinib In Pretreated Patients with Advanced Non- Small Cell Lung Cancer - Single Institution Experience
Wilmosh Mermershtain
Indian Journal of Medical and Paediatric Oncology, 2006
View PDFchevron_right
F CMAR 138643 comparison of gefitinib as first and second line therapy for
nishant patel
cancer managment and research, 2017
View PDFchevron_right
Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors
Andres Gomez
Cancer Epidemiology, 2013
View PDFchevron_right
Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
Marwan Fakih
Current Oncology, 2010
View PDFchevron_right
Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
ramon salazar
Clinical Cancer Research, 2008
View PDFchevron_right
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
Francesco Grossi
Cancer Chemotherapy and Pharmacology, 2012
View PDFchevron_right
Phase I Study of Gefitinib plus FOLFIRI in Previously Untreated Patients with Metastatic Colorectal Cancer
Craig Earle
Clinical Colorectal Cancer, 2006
View PDFchevron_right
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Saulius Cicenas
The Lancet Oncology, 2010
View PDFchevron_right
P3.01-042 Efficacy & Tolerability of Afatinib in NSCLC Patients Prior Exposure to 1st Generation EGFR TKI: Thailand Multicenter Study
Busyamas Chewaskulyong
Journal of Thoracic Oncology, 2017
View PDFchevron_right
Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer
Pieter E Postmus
Journal of Thoracic Oncology, 2010
View PDFchevron_right
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation
Janette Greenhalgh
Health Technology Assessment, 2015
View PDFchevron_right
Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Farah Fatmawati
Asian Journal of Oncology, 2018
View PDFchevron_right
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
Keisuke Baba
Medical Oncology
View PDFchevron_right
Gefitinib Plus Celecoxib in Chemotherapy-Na??ve Patients with Stage IIIB/IV Non-small Cell Lung Cancer
William Fisher
Journal of Thoracic Oncology, 2008
View PDFchevron_right
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Jesus alberto Corral
The Lancet Oncology, 2017
View PDFchevron_right
Managing Dermatologic Toxicities of Epidermal Growth Factor Receptor Inhibitors
Lillian Chou
Clinical Lung Cancer, 2007
View PDFchevron_right
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer
Alberto Zaniboni
Cancer, 2007
View PDFchevron_right
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Non-Small Cell Lung Cancer with G719X/L861Q/S768I Mutations
Ming-shyan Huang
Annals of Oncology, 2014
View PDFchevron_right
Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study
Fiona Abell
Asia-Pacific Journal of Clinical Oncology, 2012
View PDFchevron_right
A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small cell lung cancer with wild-type EGFR: The Okayama Lung Cancer Study Group Trial 1202 (OLCSG1202)
Nobukazu Fujimoto
Annals of Oncology, 2017
View PDFchevron_right
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer
Alain Gelibter
Current Medical Research and Opinion, 2007
View PDFchevron_right
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy
Vladimir Moiseyenko
European Journal of Cancer, 2015
View PDFchevron_right
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
JOSE LUIS RAMIREZ
The Lancet Oncology
View PDFchevron_right